MedTrace Logo

Biomarkers of Response to Ketamine in Depression: MRI and Blood Assays Before and After Open Label Intranasal Ketamine

NCT04216888 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2021-01-22

No results posted yet for this study

Summary

This pilot study aims to identify predictors of response to intranasal ketamine treatment in patients with treatment-resistant depression. Participants will give a sample of blood and undergo magnetic resonance imaging before and after a single intranasal ketamine treatment. Participants will subsequently receive a second intranasal ketamine treatment.

Conditions

  • Depressive Disorder, Treatment-Resistant

Interventions

DRUG

Ketamine Hydrochloride

Intranasal administration of 40mg ketamine hydrochloride using an intranasal mucosal atomization device

Sponsors & Collaborators

  • Dan Iosifescu

    lead OTHER

Principal Investigators

  • Dan Iosifescu, MD, MSc · Nathan Kline Institute

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-26
Primary Completion
2020-12-28
Completion
2020-12-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04216888 on ClinicalTrials.gov